Viking Global Investors LP decreased its holdings in AveXis Inc (NASDAQ:AVXS) by 19.1% in the 4th quarter, HoldingsChannel reports. The fund owned 478,338 shares of the company’s stock after selling 113,022 shares during the quarter. Viking Global Investors LP’s holdings in AveXis were worth $52,938,000 as of its most recent SEC filing.
Other large investors have also bought and sold shares of the company. Strs Ohio acquired a new position in shares of AveXis in the third quarter worth $116,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of AveXis by 57.5% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,241 shares of the company’s stock worth $137,000 after acquiring an additional 453 shares in the last quarter. QS Investors LLC acquired a new position in shares of AveXis in the fourth quarter worth $156,000. Cubist Systematic Strategies LLC grew its stake in shares of AveXis by 688.6% in the third quarter. Cubist Systematic Strategies LLC now owns 1,806 shares of the company’s stock worth $175,000 after acquiring an additional 1,577 shares in the last quarter. Finally, Teacher Retirement System of Texas acquired a new position in shares of AveXis in the third quarter worth $200,000. Institutional investors and hedge funds own 81.99% of the company’s stock.
In related news, VP Sukumar Nagendran sold 1,780 shares of the business’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $109.72, for a total value of $195,301.60. Following the completion of the sale, the vice president now directly owns 1,780 shares of the company’s stock, valued at $195,301.60. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Andrew F. Knudten sold 2,000 shares of the business’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $118.13, for a total transaction of $236,260.00. Following the completion of the sale, the vice president now directly owns 7,000 shares of the company’s stock, valued at $826,910. The disclosure for this sale can be found here. Over the last three months, insiders sold 65,560 shares of company stock valued at $7,793,030. 18.60% of the stock is owned by corporate insiders.
Shares of AveXis Inc (NASDAQ AVXS) opened at $136.93 on Friday. The stock has a market cap of $5,028.75, a price-to-earnings ratio of -18.99 and a beta of 2.02. AveXis Inc has a 1 year low of $65.23 and a 1 year high of $137.91.
AveXis (NASDAQ:AVXS) last announced its quarterly earnings results on Tuesday, February 27th. The company reported ($2.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.64) by ($0.91). analysts predict that AveXis Inc will post -7.63 EPS for the current year.
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Want to see what other hedge funds are holding AVXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AveXis Inc (NASDAQ:AVXS).
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.